Cargando…
Thymectomy in ocular myasthenia gravis—prognosis and risk factors analysis
BACKGROUND: Several retrospective studies have identified risk factors associated with ocular myasthenia gravis (OMG) generalization in non-surgical patients. However, the outcomes of OMG after thymectomy have not been investigated fully. This study aimed to explore the clinical predictors of post-t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361517/ https://www.ncbi.nlm.nih.gov/pubmed/35945595 http://dx.doi.org/10.1186/s13023-022-02454-y |
_version_ | 1784764543876988928 |
---|---|
author | Zhang, Jinwei Zhang, Zeyang Zhang, Hui Cui, Yuantao Chen, Yuan Lv, Peng Zhang, Peng |
author_facet | Zhang, Jinwei Zhang, Zeyang Zhang, Hui Cui, Yuantao Chen, Yuan Lv, Peng Zhang, Peng |
author_sort | Zhang, Jinwei |
collection | PubMed |
description | BACKGROUND: Several retrospective studies have identified risk factors associated with ocular myasthenia gravis (OMG) generalization in non-surgical patients. However, the outcomes of OMG after thymectomy have not been investigated fully. This study aimed to explore the clinical predictors of post-thymectomy OMG prognosis. METHODS: We performed a retrospective review of OMG patients who underwent thymectomy at our institution from January 2012 to December 2021. Kaplan–Meier and Cox proportional hazard regression analyses were used to evaluate associations between clinical features and prognosis. The main outcome measures were OMG conversion, complete stable remission (CSR), and clinical improvement. RESULTS: Fifty-eight patients were identified for conversion analysis. Thirteen (22.4%) developed generalized myasthenia gravis (GMG) at a median time of 12.7 (3–37.3) months from symptom onset. Repetitive nerve stimulation (RNS)-positivity was associated with increased risk of conversion to GMG (P = 0.002). Patients with histotype B2/B3 thymoma showed a higher risk of conversion (P = 0.002) than did patients with hyperplasia and AB/B1 thymoma. Fifty-two patients fulfilled the criteria for CSR and improvement. Sixteen (30.8%) achieved CSR at a median time of 28.7 (15–54) months after thymectomy. Fifteen (28.8%) showed clinical improvement at last follow up. Patients who achieved CSR showed a younger age of onset (P = 0.022), lower percentage of acetylcholine receptor antibody-seropositivity (P = 0.029). Histologically, patients with thymic hyperplasia and stage I thymoma showed a higher chance of CSR (P = 0.010) than did patients with stage II/III thymoma. Multivariate analysis revealed that RNS-positivity (hazard ratio [HR] 6.007, P = 0.021) and histotype B2/B3 thymoma (HR 4.611, P = 0.048) were associated with OMG conversion. Thymic hyperplasia and stage I thymoma (HR 0.300, P = 0.026) were associated with OMG CSR after thymectomy. CONCLUSION: For OMG patients after thymectomy, RNS-positivity and histotype B2/B3 thymoma are independent predictors of conversion to GMG. On the other hand, thymic hyperplasia and stage I thymoma independently predict CSR. |
format | Online Article Text |
id | pubmed-9361517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93615172022-08-10 Thymectomy in ocular myasthenia gravis—prognosis and risk factors analysis Zhang, Jinwei Zhang, Zeyang Zhang, Hui Cui, Yuantao Chen, Yuan Lv, Peng Zhang, Peng Orphanet J Rare Dis Research BACKGROUND: Several retrospective studies have identified risk factors associated with ocular myasthenia gravis (OMG) generalization in non-surgical patients. However, the outcomes of OMG after thymectomy have not been investigated fully. This study aimed to explore the clinical predictors of post-thymectomy OMG prognosis. METHODS: We performed a retrospective review of OMG patients who underwent thymectomy at our institution from January 2012 to December 2021. Kaplan–Meier and Cox proportional hazard regression analyses were used to evaluate associations between clinical features and prognosis. The main outcome measures were OMG conversion, complete stable remission (CSR), and clinical improvement. RESULTS: Fifty-eight patients were identified for conversion analysis. Thirteen (22.4%) developed generalized myasthenia gravis (GMG) at a median time of 12.7 (3–37.3) months from symptom onset. Repetitive nerve stimulation (RNS)-positivity was associated with increased risk of conversion to GMG (P = 0.002). Patients with histotype B2/B3 thymoma showed a higher risk of conversion (P = 0.002) than did patients with hyperplasia and AB/B1 thymoma. Fifty-two patients fulfilled the criteria for CSR and improvement. Sixteen (30.8%) achieved CSR at a median time of 28.7 (15–54) months after thymectomy. Fifteen (28.8%) showed clinical improvement at last follow up. Patients who achieved CSR showed a younger age of onset (P = 0.022), lower percentage of acetylcholine receptor antibody-seropositivity (P = 0.029). Histologically, patients with thymic hyperplasia and stage I thymoma showed a higher chance of CSR (P = 0.010) than did patients with stage II/III thymoma. Multivariate analysis revealed that RNS-positivity (hazard ratio [HR] 6.007, P = 0.021) and histotype B2/B3 thymoma (HR 4.611, P = 0.048) were associated with OMG conversion. Thymic hyperplasia and stage I thymoma (HR 0.300, P = 0.026) were associated with OMG CSR after thymectomy. CONCLUSION: For OMG patients after thymectomy, RNS-positivity and histotype B2/B3 thymoma are independent predictors of conversion to GMG. On the other hand, thymic hyperplasia and stage I thymoma independently predict CSR. BioMed Central 2022-08-09 /pmc/articles/PMC9361517/ /pubmed/35945595 http://dx.doi.org/10.1186/s13023-022-02454-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zhang, Jinwei Zhang, Zeyang Zhang, Hui Cui, Yuantao Chen, Yuan Lv, Peng Zhang, Peng Thymectomy in ocular myasthenia gravis—prognosis and risk factors analysis |
title | Thymectomy in ocular myasthenia gravis—prognosis and risk factors analysis |
title_full | Thymectomy in ocular myasthenia gravis—prognosis and risk factors analysis |
title_fullStr | Thymectomy in ocular myasthenia gravis—prognosis and risk factors analysis |
title_full_unstemmed | Thymectomy in ocular myasthenia gravis—prognosis and risk factors analysis |
title_short | Thymectomy in ocular myasthenia gravis—prognosis and risk factors analysis |
title_sort | thymectomy in ocular myasthenia gravis—prognosis and risk factors analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361517/ https://www.ncbi.nlm.nih.gov/pubmed/35945595 http://dx.doi.org/10.1186/s13023-022-02454-y |
work_keys_str_mv | AT zhangjinwei thymectomyinocularmyastheniagravisprognosisandriskfactorsanalysis AT zhangzeyang thymectomyinocularmyastheniagravisprognosisandriskfactorsanalysis AT zhanghui thymectomyinocularmyastheniagravisprognosisandriskfactorsanalysis AT cuiyuantao thymectomyinocularmyastheniagravisprognosisandriskfactorsanalysis AT chenyuan thymectomyinocularmyastheniagravisprognosisandriskfactorsanalysis AT lvpeng thymectomyinocularmyastheniagravisprognosisandriskfactorsanalysis AT zhangpeng thymectomyinocularmyastheniagravisprognosisandriskfactorsanalysis |